MedTrace Logo

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

NCT03472846 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-01-26

No results posted yet for this study

Summary

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Conditions

  • Postmenopausal Osteoporosis
  • Diabetes Type 2

Interventions

DRUG

Prolia, 60 Mg/mL Subcutaneous Solution

antiresorptive treatment with Prolia

DRUG

Teriparatide

osteoanabolic treatment with Forsteo

Sponsors & Collaborators

  • St. Vincent Hospital, Vienna

    collaborator OTHER

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2022-09-01
Completion
2022-09-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472846 on ClinicalTrials.gov